Opyl (ASX:OPL) - CEO, Michelle Gallaher - The Market Herald
CEO, Michelle Gallaher
Sourced: Startup Daily
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical tech support company Opyl (OPL) has completed an off-market share buy-back facility for eligible shareholders who held unmarketable parcels in the company as of February 18
  • Shareholders had until April 6 to either opt-out of the facility or increase their shareholding to more than a marketable parcel
  • Those who exercised neither option by the closing time had their shares bought-back by Opyl at 17.7 cents per share
  • The buy-back price was equal to the volume-weighted average price for the five-day trading period preceding the closing date
  • All up, Opyl has acquired and cancelled more than 370,000 shares through the facility
  • The company will advise eligible shareholders of any relevant remittance of shares as soon as practicable after April 16
  • Opyl shares are in the grey, last trading at 20.5 cents each

Medical tech support provider Opyl (OPL) has completed an off-market share buy-back facility for eligible shareholders who held unmarketable parcels in the company as of February 18.

Based in Melbourne, Opyl provides biopharma and health organisations access to emerging automated intelligence-assisted technologies and data insights to improve healthcare design, development and delivery.

The company gave impacted shareholders until April 6 to either opt-out of the facility or increase their shareholding to more than a marketable parcel.

Those shareholders who chose not to exercise either option by the closing time had their shares bought-back by Opyl at 17.7 cents per share.

The buy-back price equalled the volume-weighted average price for the five-day trading period preceding the closing date.

All up, Opyl has acquired and cancelled more than 370,000 shares through the facility.

OPL says it will advise eligible shareholders of any relevant remittance of shares as soon as practicable after April 16.

Last month, Opyl received commitments for a $1.38 million share placement aimed at accelerating company growth.

Opyl shares are in the grey, last trading at 20.5 cents at 12:31 pm AEST.

OPL by the numbers
More From The Market Online

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on…

4DMedical (ASX:4DX) to take part in US Veterans study into lung damage

It's called a burn pit: where members of the US armed forces dump unwanted and contaminated…

Proteomics International subsidiary secures European patent for OxiDx technology

Proteomics International Laboratories (ASX: PIQ) has announced that its subsidiary, OxiDx, has secured a patent across…

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at…